{"id":7700,"date":"2025-06-27T16:58:51","date_gmt":"2025-06-27T13:58:51","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=7700"},"modified":"2025-06-27T16:58:51","modified_gmt":"2025-06-27T13:58:51","slug":"the-evolving-role-of-nonsteroidal-mras-in-cardiorenal-disease","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/the-evolving-role-of-nonsteroidal-mras-in-cardiorenal-disease\/","title":{"rendered":"The Evolving Role of Nonsteroidal MRAs in Cardiorenal Disease"},"content":{"rendered":"
The Evolving Role of Nonsteroidal MRAs in Cardiorenal Disease<\/div>\n
<\/div>\n
Source: ReachMD CME Transcript \u2013 \u201cExpert Perspectives on Nonsteroidal MRAs and Cardiorenal Protection\u201d<\/div>\n
(Published 3 days ago)<\/div>\n
<\/div>\n
Cardiorenal Disease Overview<\/div>\n
<\/div>\n
Cardiovascular and kidney diseases often coexist (Cardiorenal Syndrome), with studies showing that up to 40\u201350% of patients with chronic heart failure also have chronic kidney disease (CKD).<\/div>\n
<\/div>\n
MRAs may be considered to reduce hospitalizations in patients with HFpEF and HFmrEF (i.e., mildly reduced ejection fraction), with a Class IIb recommendation\u2014particularly in those with elevated natriuretic peptides, clinical congestion, and a history of prior hospitalization.<\/div>\n
<\/div>\n
New Biomarker Mechanism Identified<\/div>\n
<\/div>\n
A recent study published in the Journal of the American Society of Nephrology (June 19, 2025) identified a novel molecular mechanism:<\/div>\n
\u2022 The cardiac LIM protein (CSRP3) is released into the bloodstream after acute cardiorenal injury (e.g., post\u2013cardiac arrest).<\/span><\/div>\n
\u2022 It is absorbed by the kidneys via megalin-mediated endocytosis, promoting fibrosis and vascular remodeling.<\/span><\/div>\n
<\/div>\n
Why Nonsteroidal MRAs Matter<\/div>\n
<\/div>\n
1. Mechanism & Safety Profile<\/div>\n
\u2022 Selectively inhibit mineralocorticoid receptors without binding to steroid hormone receptors.<\/span><\/div>\n
\u2022 This leads to targeted cardiorenal protection with fewer endocrine side effects.<\/span><\/div>\n
<\/div>\n
2. Clinical Benefits in T2D & CKD<\/div>\n
\u2022 Trials such as FIDELIO-DKD and FIGARO-DKD show significant reductions in:<\/span><\/div>\n
\u2022 Albuminuria<\/span><\/div>\n
\u2022 CKD progression<\/span><\/div>\n
\u2022 Heart failure hospitalizations<\/span><\/div>\n
\u2022 Cardiovascular events<\/span><\/div>\n
<\/div>\n
3. Expanded Role in Heart Failure<\/div>\n
\u2022 Nonsteroidal MRAs also improve:<\/span><\/div>\n
\u2022 Cardiac remodeling<\/span><\/div>\n
\u2022 Inflammation<\/span><\/div>\n
\u2022 Myocardial fibrosis<\/span><\/div>\n
\u2022 Supporting better cardiac function in heart failure patients.<\/span><\/div>\n
<\/div>\n
4. Emerging Evidence in Type 1 Diabetes<\/div>\n
\u2022 The ongoing FINE-ONE trial is assessing finerenone in T1D with albuminuria, potentially expanding its indication in CKD.<\/span><\/div>\n
<\/div>\n
5. Future Pipeline<\/div>\n
\u2022 Novel agents in development include:<\/span><\/div>\n
\u2022 Ocedurenone (Phase III for CKD-related hypertension)<\/span><\/div>\n
\u2022 Exaserone (next-generation MRA)<\/span><\/div>\n
\u2022 Both aim to improve safety and tolerability profiles.<\/span><\/div>\n
<\/div>\n
6. Clinical Implementation<\/div>\n
\u2022 CME guidance now emphasizes:<\/span><\/div>\n
\u2022 Initiation strategies<\/span><\/div>\n
\u2022 Dose titration<\/span><\/div>\n
\u2022 Monitoring protocols<\/span><\/div>\n
\u2022 Hyperkalemia management in real-world practice<\/span><\/div>\n
<\/div>\n
Conclusion<\/div>\n
<\/div>\n
MRAs\u2014especially nonsteroidal agents like finerenone\u2014are transforming the management of cardiorenal disease by offering dual organ protection with a well-tolerated safety profile.<\/div>\n
As evidence continues to grow, especially in CKD-only and T1D populations, these agents are becoming essential therapeutic partners alongside SGLT2 inhibitors and RAS blockers in the evolving CKM care landscape.<\/div>\n
<\/div>\n
https:\/\/click.mail.medscape.org\/?qs=baceda4cdd280a18831080ccc485baf32915345193e21fe668df4472f353c0eb9088b28825163e766c361ba79db0fcba1bb4c4080904c9d2def548aea18fbb09<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

The Evolving Role of Nonsteroidal MRAs in Cardiorenal Disease Source: ReachMD CME Transcript \u2013 \u201cExpert Perspectives on Nonsteroidal MRAs and Cardiorenal Protection\u201d (Published 3 days ago) Cardiorenal Disease Overview Cardiovascular and kidney diseases often coexist (Cardiorenal Syndrome), with studies showing that up to 40\u201350% of patients with chronic heart failure also have chronic kidney disease […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7700","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7700","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=7700"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7700\/revisions"}],"predecessor-version":[{"id":7704,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7700\/revisions\/7704"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=7700"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=7700"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=7700"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}